Get the Stockscreener App
41.53
4.93%
1.95
Soleno Therapeutics Inc stock is traded at $41.53, with a volume of 1.43M.
It is up +4.93% in the last 24 hours and down -9.99% over the past month.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
See More
Previous Close:
$39.58
Open:
$40.32
24h Volume:
1.43M
Relative Volume:
0.78
Market Cap:
$2.23B
Revenue:
-
Net Income/Loss:
$-38.99M
P/E Ratio:
-13.86
EPS:
-2.9966
Net Cash Flow:
$-24.94M
1W Performance:
+7.70%
1M Performance:
-9.99%
6M Performance:
-48.85%
1Y Performance:
-18.54%
1-Day Range:
$39.55
$41.80
1-Week Range:
$39.23
$44.70
52-Week Range:
$37.95
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
41.53 | 2.13B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Oct-07-25 | Initiated | Goldman | Buy |
| Aug-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-23-25 | Initiated | TD Cowen | Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Dec-02-24 | Reiterated | Robert W. Baird | Outperform |
| Dec-02-24 | Reiterated | Stifel | Buy |
| Sep-03-24 | Initiated | H.C. Wainwright | Buy |
| May-10-24 | Initiated | Robert W. Baird | Outperform |
| Feb-05-24 | Initiated | Piper Sandler | Overweight |
| Jan-23-24 | Initiated | Stifel | Buy |
| Nov-21-23 | Resumed | Guggenheim | Buy |
| Sep-29-20 | Initiated | Guggenheim | Buy |
| Jan-10-20 | Initiated | Craig Hallum | Buy |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
Pullback Watch: Why is Soleno Therapeutics Inc. stock going downMarket Growth Report & Fast Moving Market Watchlists - baoquankhu1.vn
Why a biotech is drawing attention to a rare disease at the Super Bowl - Medical Marketing and Media
(SLNO) Movement as an Input in Quant Signal Sets - Stock Traders Daily
VYKAT XR Launch Momentum Could Be A Game Changer For Soleno Therapeutics (SLNO) - Yahoo Finance
A Look At Soleno Therapeutics (SLNO) Valuation As VYKAT XR Launch Shapes A “Transformational” 2025 - Yahoo Finance
A Look At Soleno Therapeutics (SLNO) Valuation After VYKAT XR Launch And Upcoming 2025 Business Updates - Sahm
Published on: 2026-02-03 13:03:09 - baoquankhu1.vn
Soleno Therapeutics (NASDAQ:SLNO) Stock Price Up 8.3%Time to Buy? - MarketBeat
Soleno Therapeutics stock jumps nearly 9% today — what SLNO traders are watching next - TechStock²
Down 18.3% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround - Yahoo Finance
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: A Compelling 190% Upside Potential - DirectorsTalk Interviews
Universal Beteiligungs und Servicegesellschaft mbH Sells 32,627 Shares of Soleno Therapeutics, Inc. $SLNO - MarketBeat
Risk Hedge: Is Diebold Nixdorf Incorporated a good ESG investmentRate Cut & Precise Swing Trade Alerts - baoquankhu1.vn
Sell Signal: Will Soleno Therapeutics Inc outperform the market in YEAR2025 Key Highlights & Verified Swing Trading Watchlist - baoquankhu1.vn
Soleno Therapeutics stock hits 52-week low at 39.42 USD By Investing.com - Investing.com South Africa
Soleno Therapeutics Shares Dip Following $200 Million Stock Offering Pricing - MSN
Soleno Therapeutics (NASDAQ:SLNO) Hits New 52-Week LowShould You Sell? - MarketBeat
Soleno Therapeutics stock hits 52-week low at 39.42 USD - Investing.com
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug - MSN
Soleno Therapeutics to Participate in Upcoming Conferences - The Manila Times
Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (GEHC) and Soleno Therapeutics (SLNO) - The Globe and Mail
Solena Therapeutics (SLNO) Stock Under Pressure But Upside is Huge - Finviz
Soleno Therapeutics (SLNO) Stock Analysis: Unveiling a Potential 164% Upside in the Biotech Arena - DirectorsTalk Interviews
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Liquidity Mapping Around (SLNO) Price Events - Stock Traders Daily
Soleno Therapeutics Updates Executive Compensation and Severance Plans - The Globe and Mail
Is Soleno Therapeutics, Inc. (NASDAQ:SLNO) The Best Under $50 Stock to Buy Now? - Insider Monkey
Emerald Mutual Fund Advisers Trust Reduces Position in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Soleno Therapeutics Inc. (SLNO): Analysts See Major Upside - Finviz
Soleno Therapeutics (SLNO) Valuation Checked After New Q4 2025 Revenue Guidance - Sahm
FY2025 Earnings Estimate for SLNO Issued By HC Wainwright - MarketBeat
Emerald Advisers LLC Trims Position in Soleno Therapeutics, Inc. $SLNO - MarketBeat
SLNO INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Soleno Therapeutics, Inc. - ACCESS Newswire
Q2 EPS Estimate for Soleno Therapeutics Increased by Analyst - MarketBeat
Soleno Therapeutics stock price target raised to $120 from $110 at H.C. Wainwright - Investing.com Nigeria
Soleno Therapeutics stock price target raised to $120 from $110 at H.C. Wainwright By Investing.com - Investing.com South Africa
Soleno Therapeutics (SLNO): Wells Fargo Raises Price Target to $114 | SLNO Stock News - GuruFocus
Johnson Fistel Begins Investigation on Behalf of Soleno - GlobeNewswire
Wells Fargo Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Raises Target Price to $114 - 富途资讯
Soleno Therapeutics (SLNO) may find a bottom soon, here's why you should buy the stock now - MSN
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Exploring A 160% Potential Upside - directorstalkinterviews.com
SLNO INVESTOR ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Fraud Investigation - GlobeNewswire
Momentum Shift: What is Soleno Therapeutics Incs revenue forecast2025 Year in Review & Consistent Growth Equity Picks - baoquankhu1.vn
Market Outlook: Is Soleno Therapeutics Inc forming a breakout patternJuly 2025 Momentum & Long Hold Capital Preservation Plans - baoquankhu1.vn
Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid - GlobeNewswire
Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKAT XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman - GlobeNewswire Inc.
Dow Update: Is Monogram Technologies Inc trading at a discountWeekly Stock Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
Q4 EPS Estimate for Soleno Therapeutics Increased by Analyst - MarketBeat
Soleno Therapeutics (SLNO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Finviz
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):